♥aetna®

MEDICARE FORM

Viscosupplementation Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

For Illinois MMP:
FAX: 1-855-320-8445
PHONE: 1-866-600-2139

For other lines of business:
Please use other form.

Note: Single injection: Durolane and Gel-One are non-preferred. Monovisc and Synvisc-One are preferred. Multi-injection: Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Supartz FX, Trivisc, and Visco-3 are non-preferred. Orthovisc and Synvisc are preferred.

Please indicate: ☐ Start of treatment: Start date ___/___/___   ☐ Continuation of therapy (Request Additional Series Below)
Precertification Requested By: _____   Phone: _____   Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:

Address: _____   City: _____   State: _____   ZIP: _____

Home Phone: _____   Work Phone: _____   Cell Phone: _____

DOB: _____   Allergies: _____   Email: _____

Current Weight: _____ lbs or _____ kgs   Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____   Does patient have other coverage? ☐ Yes ☐ No
Group #: _____   If yes, provide ID#: _____   Carrier Name: _____
Insured: _____   Insured: _____

C. PRESCRIBER INFORMATION

First Name: _____   Last Name: _____   *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.

Address: _____   City: _____   State: _____   ZIP: _____

Phone: _____   Fax: _____   St Lic #: _____   NPI #: _____   DEA #: _____   UPIN: _____

Provider Email: _____   Office Contact Name: _____   Phone: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered   ☐ Physician's Office   ☐ Home
☐ Outpatient Infusion Center
    Center Name: _____
☐ Home Infusion Center   Phone: _____
    Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____
City: _____   State: _____   ZIP: _____
Phone: _____   Fax: _____
TIN: _____   PIN: _____
NPI: _____

Dispensing Provider/Pharmacy:
☐ *Outpatient Dialysis Center*   ☐ Physician's Office
☐ Retail Pharmacy   ☐ Specialty Pharmacy
☐ Mail Order   ☐ Other: _____
Name: _____
Address: _____
City: _____   State: _____   ZIP: _____
Phone: _____   Fax: _____
TIN: _____   PIN: _____
NPI: _____

E. PRODUCT INFORMATION

Request is for: ☐ Euflexxa (1% sodium hyaluronate) ☐ Durolane (hyaluronic acid) ☐ Gel-One (cross-linked hyaluronate)
☐ Gelsyn-3 (sodium hyaluronate) ☐ GenVisc 850 (sodium hyaluronate) ☐ Hyalgan (sodium hyaluronate) ☐ Supartz FX (sodium hyaluronate)
☐ Hymovis (high molecular weight viscoelastic hyaluronan) ☐ Orthovisc (high molecular weight hyaluronan) ☐ Monovisc (sodium hyaluronate)
☐ Synvisc (hylan G-F 20) ☐ Synvisc-One (hylan G-F 20) ☐ TriVisc (sodium hyaluronate) ☐ Visco-3 (sodium hyaluronate)
☐ Synojoynt (1% sodium hyaluronate) ☐ Triluron (1% sodium hyaluronate)
Dose: _____   **Frequency:** _____   **HCPCS Code:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____   Secondary ICD Code: _____   Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its _entirety_ for all precertification requests.

For All Requests (includes Medicare patient requests, clinical documentation required for all requests):

Note: Single injection products: Durolane and Gel-One are non-preferred. The preferred products are Monovisc and Synvisc-One.

Multi injection products: Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Supartz FX, TriVisc and Visco-3 are non-preferred. The preferred products are Orthovisc and Synvisc.

☐ Yes ☐ No   Has the patient had prior therapy with the requested viscosupplementation product within the last 365 days?
☐ Yes ☐ No   Has the patient had a trial and failure, intolerance, or contraindication to any of the following (select all that apply)
        ☐ Monovisc   ☐ Orthovisc   ☐ Synvisc   ☐ Synvisc-One

Continued on next page

GR-68744-5 (1-23)

♥aetna®

For Illinois MMP:
FAX: 1-855-320-8445
PHONE: 1-866-600-2139

For other lines of business:
Please use other form.

Note: Single injection: Durolane and Gel-One are non-preferred. Monovisc and Synvisc-One are preferred. Multi-injection: Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Supartz FX, Trivisc, and Visco-3 are non-preferred. Orthovisc and Synvisc are preferred.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its <u>entirety</u> for all precertification requests.

Please explain if there are any other medical reason(s) that the patient cannot use any of the following (select all that apply)
☐ Monovisc ☐ Orthovisc ☐ Synvisc ☐ Synvisc-One

_____

☐ Yes ☐ No Does the patient have documented symptomatic osteoarthritis (OA) of the tibiofemoral articulation of the knee?
→ Which knee will the viscosupplement be used? ☐ Left knee ☐ Right knee ☐ Both knees
☐ Yes ☐ No Is there radiologic evidence of osteoarthritis (OA) of the knee?
→ ☐ Yes ☐ No Is the patient symptomatic?
→ Which of the following documented symptoms of osteoarthritis (OA) does the patient have? (Check ALL that apply)
☐ Knee Pain ☐ Bony enlargement ☐ Bony tenderness ☐ Crepitus (noisy, grating sound) on active motion
☐ Erythrocyte sedimentation rate (ESR) less than 40 mm/hr ☐ Less than 30 minutes of morning stiffness
☐ No palpable warmth of synovium ☐ Over 50 years of age
☐ Rheumatoid factor less than 1:40 titer (agglutination method)
☐ Synovial fluid signs (clear fluid of normal viscosity and WBC less than 2000/mm3)
→ Which of the following radiologic findings support the clinical diagnosis of osteoarthritis (OA)?
Please select: ☐ Joint space narrowing ☐ Subchondral sclerosis ☐ Osteophytes and sub-chondral cysts
☐ Yes ☐ No Does the patient have knee pain that interferes with functional activities (e.g. ambulation or prolonged standing)?
☐ Yes ☐ No Can the knee pain be attributed to any other forms of joint disease (other than osteoarthritis)?
☐ Yes ☐ No Has the patient completed conservative therapy in each joint to be treated with viscosupplementation?
→ ☐ Yes ☐ No Is the patient unable to tolerate conservative therapy because of adverse side effects?
→ Please indicate which of the following conservative therapies the patient completed:
☐ Physical therapy ☐ Acetaminophen ☐ Topical capsaicin cream ☐ NSAID's, Specify: _____
☐ Other: please explain: _____
☐ Yes ☐ No Has the conservative treatment resulted in functional improvement after therapy?
☐ Yes ☐ No Has the patient failed to adequately respond to aspiration and injection of intra-articular steroids?
☐ Yes ☐ No Are there any contraindications to the patient receiving viscosupplementation injections (e.g. active joint infection, bleeding disorder or skin infections at the injection site)?
☐ Yes ☐ No Is the patient scheduled to undergo a total knee replacement within 6 months of starting viscosupplementation treatment?
☐ Yes ☐ No Will the drug requested be used concomitantly with any of the following?
→ Please select: ☐ With intra-articular anesthetics ☐ With intra-articular corticosteroids ☐ With intra-articular platelet rich plasma
☐ With intra-articular mannitol/sorbitol ☐ With intra-articular mesenchymal stem cells ☐ With another viscosupplement
☐ Yes ☐ No Does the patient have morning stiffness of less than 30 minutes in duration?
☐ Yes ☐ No Does the patient have crepitus on motion of the knee?

For All Additional Series Requests (clinical documentation required for all requests):
What product did the patient last receive? _____
Enter date of last injection from prior series: ____ / ____ / ____
☐ Yes ☐ No Have at least six months elapsed since the last injection in the prior series?
☐ Yes ☐ No Has the patient had a documented reduction in the dose of NSAID's, other anti-inflammatories, or other analgesics during the 6-month period following the previous injection series?
→ ☐ Yes ☐ No Does the patient require NSAID's, other anti-inflammatories, or other analgesics for a comorbid medical condition in addition to OA of the knee? **If yes,** please identify the comorbid medical condition: _____
☐ Yes ☐ No ☐ N/A Was there a reduction in the number of intra-articular steroid injections or aspirations during the 6-month period following the series?
☐ Yes ☐ No Is there objective documentation to support significant improvement of functional capacity as a result of previous injection series?
☐ Yes ☐ No Is there objective documentation to support significant improvement in pain as a result of previous injections?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.